The global anti-obesity drugs market was is valued at $1.3bn in 2017

Monday, December 24, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 24, 2018 /PRNewswire/ -- Mechanism of Action, Innovator Drugs, Generics. Prescription Drugs, OTC, Duration of Therapy, Incretin mimetics/GLP-1 agonists, SNDRIs, Lipase Inhibitors, Serotonin receptor agonists, Sympathomimetic-GABA receptor agonists, Sympathomimetics, Short-term Drugs, Long-term Drugs

Read the full report: https://www.reportlinker.com/p04763516 The global anti-obesity drugs market was is valued at $1.3bn in 2017 and is expected to grow at a CAGR of 29.1% from 2017 to 2022. In 2017, the prescription
drugs submarket held 96% of the global anti-obesity drugs market.How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 250-page report you will receive 119 tables and 139 figures– all unavailable elsewhere.The 250-page report provides clear detailed insight into the anti-obesity drugs market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today you stay better informed and ready to act.Report Scope- Global Anti-obesity Drugs Market forecast from 2018-2028Global Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Mechanism of Action:- Incretion mimetics/GLP-1 agonists- SNDRIs- Lipase Inhibitors- Serotonin receptor agonists- Sympathomimetic-GABA receptor agonists- SympathomimeticsGlobal Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Duration of Therapy:- Long-term Drugs- Short-term DrugsGlobal Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Innovator vs Generic Drugs:- Innovator- Generic DrugsGlobal Anti-obesity Drugs Market analysis and forecast from 2018-2028, by Prescription vs OTC:- Prescription Drugs- OTCThis report discusses and provides revenue forecasts from 2018-2028 for selected anti-obesity drugs:- Saxenda- Contrave/Mysimba- Belviq- Qysmia- Xenical- AlliThis report provides individual revenue forecasts from 2018-2028 for these regional and national markets:- US- Japan- EU5: Germany, France, Spain, Italy, UK- BRIC: Brazil, Russia, China, India- RoWEach national market is further segmented by submarket: mechanism of action, duration of therapy, prescription vs OTC, innovator vs generic drugsOur study discusses the selected leading companies that are the major players in the anti-obesity drugs market:- Eisai/Arena- GlaxoSmithKline (GSK)- Novo Nordisk- Orexigen/Takeda- Roche- Teva- VivusThis report discusses novel mechanism of action, active pipeline molecules and promising pipeline molecules.This report gives an overview of pricing and reimbursement in the US and EU.This report provides a SWOT Analysis of the global anti-obesity drugs market.Read the full report: https://www.reportlinker.com/p04763516 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-anti-obesity-drugs-market-was-is-valued-at-1-3bn-in-2017--300770619.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store